Abstract
SSR181507 ((3-exo)-8-benzoyl-N-[[(2S)7-chloro-2,3-dihydro-1,4-benzodioxin-1-yl]methyl]-8-azabicyclo[3.2.1]octane-3-methanamine monohydrochloride) is a novel tropanemethanamine benzodioxane derivative that possesses high and selective affinities for D2-like and 5-HT1A receptors (KI=0.8, 0.2, and 0.2 nM for human D2, D3, and 5-HT1A, respectively). In vivo, SSR181507 inhibited [3H]raclopride binding to D2 receptors in the rat (ID50=0.9 and 1 mg/kg, i.p. in limbic system and striatum, respectively). It displayed D2 antagonist and 5-HT1A agonist properties in the same concentration range in vitro (IC50=5.3 nM and EC50=2.3 nM, respectively, in the GTPγS model) and in the same dose range in vivo (ED50=1.6 and 0.7 mg/kg, i.p. on striatal DA and 5-HT synthesis, respectively, and 0.03–0.3 mg/kg, i.v. on dorsal raphe nucleus firing rate). It selectively enhanced Fos immunoreactivity in mesocorticolimbic areas as compared to the striatum. This regional selectivity was confirmed in electrophysiological studies where SSR181507, given acutely (0.1–3 mg/kg, i.p.) or chronically (3 mg/kg, i.p., o.d., 22 days), increased or decreased, respectively, the number of spontaneous active DA cells in the ventral tegmental area, but not in the substantia nigra. Moreover, SSR181507 increased both basal and phasic DA efflux (as assessed by microdialysis and electrochemistry) in the medial prefrontal cortex and nucleus accumbens, but not in the striatum. This study shows that the combination of D2 receptor antagonism and 5-HT1A agonism, in the same dose range, confers on SSR181507 a unique neurochemical and electrophysiological profile and suggests the potential of this compound for the treatment of the main dimensions of schizophrenia.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Alonso R, Voutsinos B, Fournier M, Labie C, Steinberg R, Souilhac J et al (1999). Blockade of cannabinoid receptors by SR141716 selectively increases fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function. Neuroscience 91: 607–620.
Arborelius LE, Nomikos GG, Hacksell U, Svenson TH (1993). (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol Scand 148: 465–466.
Bantick RA, Deakin JF, Grasby PM (2001). The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 15: 37–46.
Bonhaus DW, Bach C, De Souza A, Salazar FHR, Matsuoka BD, Zuppan P et al (1995). The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br J Pharmacol 115: 622–628.
Borison RL, Albrecht JW, Diamond BL (1990). Efficacy and safety of a putative anxiolytic agent: ipsapirone. Psychopharmacol Bull 26: 207–210.
Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F (1995). Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166: 68–72.
Briley M, Langer SZ (1978). Two binding sites for 3H-spiroperidol on rat striatal membranes. Eur J Pharmacol 50: 283–284.
Brun P, Steinberg R, Le Fur G, Soubrié P (1995). Blockade of neurotensin receptor by SR 48692 potentiates the facilitatory effect of haloperidol on the evoked in vivo dopamine release in the rat nucleus accumbens. J Neurochem 64: 2073–2079.
Buckley NJ, Bonner TI, Buckley CM, Brann MR (1989). Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol 35: 469–476.
Burnet PWJ, Eastwood SL, Harrison PJ (1996). 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 15: 442–455.
Cheng Y, Prusoff WH (1973). Relationship between the inhibition constant (Ki) and the concentration of the inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22: 3099–3108.
Dearry A, Gringrich JA, Falardeau P, Fremeau RT, Bates MD, Caron MG (1990). Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature 347: 72–76.
Depoortere R, Boulay D, Perrault G, Bergis O, Decobert M, Françon D et al SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II. Behavioral profile predictive of an atypical antipsychotic activity. Neuropsychopharmacology, 2003.
Depoortere R, Boulay D, Perrault G, Sanger DJ (2002). Behavioral pharmacology of dopamine D2 and D3 receptors: use of the knock-out mice approach. In: Di Chiara G (ed) Dopamine in the CNS II. Springer: Heidelberg. pp 239–264.
Deutch AY, Lee MC, Iadarola MJ (1992). Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 3: 332–341.
Furchgott RF (1972). The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. In: Blaschko H, Muscholl E (eds) Handbook of Experimental Pharmacology Vol. XXXIII Springer: Berlin, Heidelberg, New York. pp 283–335.
Goff D, Midha K, Brotman A, McCormick S, Waites M, Amico E (1991). An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 11: 193–197.
Grace AA, Bunney BS (1983). Intracellular and extracellular electrophysiology of nigral dopaminergic neurons 1. Identification and characterization. Neuroscience 10: 301–315.
Grandy DK, Marchionni MA, Makam H, Stofko RE, Alfano M, Frothingham L et al (1989). Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc Natl Acad Sci USA 86: 9762–9766.
Greengrass P, Bremner R (1979). Binding characteristics of 3H-prazosin to rat brain alpha-adrenergic receptors. Eur J Pharmacol 55: 323–326.
Haigler HJ, Aghajanian GK (1974). Lysergic acid diethylamide and serotonin: a comparison of effects on serotonergic neurons and neurons receiving a serotonergic inputs. J Pharmacol Exp Ther 188: 688–699.
Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY (2001). 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76: 1521–1531.
Jones-Humble SA, Durcan MJ, Lyerly D, Norton RM, Tang FLM, Russell AV et al (1996). Preclinical neurochemical and electrophysiological profile of 1192U90 a potential antipsychotic. Neuropsychopharmacology 15: 217–230.
Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (2002). The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441: 137–140.
Kapur S, Remington G (1996). Serotonin–dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153: 466–476.
Kasper S, Tauscher J, Willeit M, Stamenkovic M, Neumeister A, Kufferle B et al (2002). Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder implication for psychopharmacology. World J Biol Psychiatry 3: 133–146.
Kenny BA, Chalmers DH, Philpott PC, Naylor AM (1995). Characterization of an alpha 1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline. Br J Pharmacol 115: 981–986.
Köhler C, Hall H, Ogren SO, Gawell L (1985). Specific in vitro and in vivo binding of 3H-raclopride, a potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 34: 2251–2259.
Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J (1993). Depression in first-episode schizophrenia. Am J Psychiatry 150: 1643–1648.
Kuroki T, Meltzer HY, Ichikawa J (1999). Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288: 774–781.
Liberman RP, Corrigan PW (1992). Is schizophrenia a neurological disorder? J Neuropsychiatry Clin Neurosci 4: 119–124.
Martin GR, Humphrey PA (1994). Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature. Neuropharmacology 33: 261–273.
Meltzer HY (1999). The role of serotonin in antipsychotic drug action. Neuropharmacology 21: 1065–1155.
Meltzer HY, McGurk SR (1999). The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25: 233–255.
Millan MJ (2000). Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors. J Pharmacol Exp Ther 295: 853–861.
Miquel MC, Doucet E, Boni C, El Mestikawy S, Mathiessen L, David G et al (1991). Central serotonin1A receptors: respective distributions of encoding mRNA, receptor protein and binding sites by in situ hybridization histochemistry, radioimmunohistochemistry and autoradiographic mapping in the rat brain. Neurochem Int 19: 453–465.
Miyamoto S, Duncan G, Mailman R, Lieberman J (2000). Developing novel antipsychotic drugs: strategies and goals. Curr Opin CPNS Invest Drugs 2: 25–39.
Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR (1993). Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 43: 320–327.
Newman-Tancredi A, Cussac D, Audinot V, Pasteau V, Cavaudan S, Millan MJ (1999). G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: a guanosine-5′-O-(3-[32S]thio)-triphosphate binding and antibody study. Mol Pharmacol 55: 564–574.
Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L et al (1998). Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors. Eur J Pharmacol 355: 245–256.
Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH (1994). Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology 115: 147–156.
Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates. Academic Press: Sydney, Australia.
Richelson E, Souder T (2000). Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci 68: 29–39.
Robertson GS, Fibiger HC (1992). Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46: 315–328.
Robinson DS, Alms DR, Shrotriya RC, Messina M, Wickramarante P (1989). Serotonergic anxiolytics and treatment of depression. Psychopathology 22: 27–36.
Rollema H, Lu Yi, Schmidt AW, Sprouse JS, Zorn SH (2000). 5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 48: 229–237.
Sakaue M, Somboonthum P, Nishihara B, Koyama Y, Hashimoto H, Baba A et al (2000). Postsynaptic 5-hydroxytryptamine (1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br J Pharmacol 129: 1028–1034.
Sanger DJ, Schoemaker H (1992). Discriminative properties of 8-OH-DPAT. Relationship to affinity for 5-HT1A receptors. Psychopharmacology 108: 85–92.
Scatton B, Sanger DJ (2000). Pharmacological and molecular targets in the search for novel antipsychotics. Behav Pharmacol 11: 242–256.
Schoemaker H (1993). [3H]7-OH-DPAT labels both dopamine D3 receptors and σ sites in the bovine caudate nucleus. Eur J Pharmacol 242: R1–R2.
Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui O, Curet O et al (1997). Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280: 83–97.
Schoemaker H, Langer SZ (1986). [3H]8-OH-DPAT labels the serotonin transporter in the rat striatum. Eur J Pharmacol 124: 371–373.
Semba J, Sakai M, Miyoshi R, Mataga N, Fukamauch F, Kito S (1996). Differential expression of c-fos mRNA in rat prefrontal cortex, striatum, n. accumbens and lateral septum after typical and atypical antipsychotics: an in situ hybridization study. Neurochem Int 29: 435–442.
Shen Y, Monsma FJ, Metcalf MA, Jose PA, Hamblin MW, Sibley D (1993). Molecular cloning and expression of 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem 268: 18200–18204.
Sibley DR, Monsma FJ (1992). Molecular biology of dopamine receptors. Trends Pharmacol Sci 13: 61–69.
Simpson MDC, Lubman DI, Slater P, Deakin JFW (1996). Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT1A receptors in ventral prefrontal cortex in schizophrenia. Biol Psychiatry 39: 919–928.
Skarsfeldt T (1995). Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 281: 289–294.
Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 247: 146–151.
Suaud-Chagny MF, Brun P, Buda M, Gonon F (1992). Fast in vivo monitoring of electrically evoked dopamine release by differential pulse amperometry with untreated carbon fibre electrodes. J Neurosci Methods 45: 183–190.
Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C et al (2001). Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158: 1722–1725.
Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Uehara T, Kurachi M et al (2000). Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol 20: 386–388.
Tremblay PO, Gervais J, Rouillard C (1998). Modification of haloperidol-induced pattern of c-fos expression by serotonin agonists. Eur J Neurosci 10: 3546–3555.
Van Tol HHM, Bunzow JR, Guan HG, Sunahara RK, Seeman P, Niznik HB et al (1991). Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610–614.
Volonté M, Monferini E, Cerutti M, Fodritto F, Borsini F (1997). BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J Neurochem 59: 182–190.
Wadenberg ML, Ahlenius S (1991). Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J Neural Transm [Gen Sect] 83: 43–53.
Weinberger DR, Lipska BK (1995). Cortical maldevelopment, antipsychotic drugs and schizophrenia: a search for common ground. Schizophr Rev 16: 87–110.
White FJ, Wang RY (1983). Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221: 1054–1057.
Acknowledgements
We thank N Brunel, G Danielou, and M Vinay for technical assistance.
Author information
Authors and Affiliations
Corresponding author
Additional information
Note: This paper is the first of two companion studies published in Neuropsychopharmacology. The second paper's citation is SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. II: Behavioral Profile Predictive of an Atypical Antipsychotic Activity (2003) 28, 1889–1902. doi: 1038/sj.npp.1300261. These two papers should be read together.
Rights and permissions
About this article
Cite this article
Claustre, Y., Peretti, D., Brun, P. et al. SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. I: Neurochemical and Electrophysiological Profile. Neuropsychopharmacol 28, 2064–2076 (2003). https://doi.org/10.1038/sj.npp.1300262
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1300262
Keywords
This article is cited by
-
F15063, a potential antipsychotic with D2/D3 antagonist, 5‐HT1A agonist and D4 partial agonist properties: (I) in vitro receptor affinity and efficacy profile
British Journal of Pharmacology (2007)
-
F15063, a compound with D2/D3 antagonist, 5‐HT1A agonist and D4 partial agonist properties: (II) Activity in models of positive symptoms of schizophrenia
British Journal of Pharmacology (2007)
-
F15063, a compound with D2/D3 antagonist, 5‐HT1A agonist and D4 partial agonist properties: (III) Activity in models of cognition and negative symptoms
British Journal of Pharmacology (2007)
-
Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats
Psychopharmacology (2007)
-
SLV313 (1-(2,3-Dihydro-Benzo[1,4]Dioxin-5-yl)-4- [5-(4-Fluoro-Phenyl)-Pyridin-3-ylmethyl]-Piperazine Monohydrochloride): A Novel Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist Potential Antipsychotic Drug
Neuropsychopharmacology (2007)
